TRIAL RESULTS · SIDE EFFECTS
Glutathione side effects
ANSWER
In 3 placebo-controlled trials with posted results, the most common side effects of Glutathione were neutrophil count decreased 23.4% (placebo 18.7%), anemia 12.8% (placebo 16.5%), peripheral sensory neuropathy 12.8% (placebo 7.7%). Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
3
with an arm on Glutathione, of 276 registered
Against placebo
3
placebo-controlled trials
People in those trials
146
on Glutathione · 143 on placebo
Read
2026-10-03
ClinicalTrials.gov
VS PLACEBO
Most common side effects, Glutathione beside placebo
Share of people with each side effect in 3 placebo-controlled trials with posted results: 146 people on Glutathione (all doses), 143 on placebo, same trials. Listed only when reported for at least half of the people on Glutathione. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
ALL TRIALS
The 100 most reported of 127 side effects reported
Every trial with posted results and an arm on Glutathione (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Glutathione | Placebo | Trials |
|---|---|---|---|---|
| Neutrophil count decreased | Investigations | 23.4% (22 of 94) | 18.7% | 1 |
| Cough | Respiratory, thoracic and mediastinal disorders | 11.3% (14 of 124) | 10.7% | 2 |
| Anemia | Blood and lymphatic system disorders | 12.8% (12 of 94) | 16.5% | 1 |
| Peripheral sensory neuropathy | Nervous system disorders | 12.8% (12 of 94) | 7.7% | 1 |
| Vomiting | Gastrointestinal disorders | 8.1% (10 of 124) | 8.3% | 2 |
| Fatigue | General disorders | 10.6% (10 of 94) | 9.9% | 1 |
| Infective pulmonary exacerbation of cystic fibrosis | Respiratory, thoracic and mediastinal disorders | 33.3% (10 of 30) | 30.0% | 1 |
| White blood cell decreased | Investigations | 9.6% (9 of 94) | 9.9% | 1 |
| Pyrexia | General disorders | 26.7% (8 of 30) | 16.7% | 1 |
| Abdominal pain | Gastrointestinal disorders | 5.6% (7 of 124) | 3.3% | 2 |
| Alopecia | Skin and subcutaneous tissue disorders | 7.4% (7 of 94) | 4.4% | 1 |
| Constipation | Gastrointestinal disorders | 4.8% (6 of 124) | 6.6% | 2 |
| Platelet count decreased | Investigations | 6.4% (6 of 94) | 11.0% | 1 |
| Anorexia | Metabolism and nutrition disorders | 6.4% (6 of 94) | 3.3% | 1 |
| Otitis media | Infections and infestations | 20.0% (6 of 30) | 3.3% | 1 |
| Sinusitis | Infections and infestations | 20.0% (6 of 30) | 10.0% | 1 |
| Thromboembolic event | Vascular disorders | 5.3% (5 of 94) | 1.1% | 1 |
| Weight decreased | Investigations | 16.7% (5 of 30) | 3.3% | 1 |
| Lymphocyte count decreased | Investigations | 4.3% (4 of 94) | 7.7% | 1 |
| Upper respiratory tract infection | Infections and infestations | 13.3% (4 of 30) | 20.0% | 1 |
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | 13.3% (4 of 30) | 3.3% | 1 |
| Alanine aminotransferase increased | Investigations | 2.4% (3 of 124) | 0.8% | 2 |
| Headache | Nervous system disorders | 2.4% (3 of 124) | 1.7% | 2 |
| Nausea | Gastrointestinal disorders | 3.2% (3 of 94) | 4.4% | 1 |
| Death NOS | General disorders | 3.2% (3 of 94) | 2.2% | 1 |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | 3.2% (3 of 94) | 3.3% | 1 |
| Viral upper respiratory tract infection | Infections and infestations | 10.0% (3 of 30) | 0.0% | 1 |
| Rash | Skin and subcutaneous tissue disorders | 10.0% (3 of 30) | 6.7% | 1 |
| Dyspepsia | Gastrointestinal disorders | 2.1% (2 of 94) | 0.0% | 1 |
| Edema limbs | General disorders | 2.1% (2 of 94) | 0.0% | 1 |
| Anaphylaxis | Immune system disorders | 2.1% (2 of 94) | 0.0% | 1 |
| Lung infection | Infections and infestations | 2.1% (2 of 94) | 1.1% | 1 |
| INR increased | Investigations | 2.1% (2 of 94) | 0.0% | 1 |
| Hyperglycemia | Metabolism and nutrition disorders | 2.1% (2 of 94) | 5.5% | 1 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 2.1% (2 of 94) | 1.1% | 1 |
| Back pain | Musculoskeletal and connective tissue disorders | 2.1% (2 of 94) | 2.2% | 1 |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 2.1% (2 of 94) | 4.4% | 1 |
| Aspiration | Respiratory, thoracic and mediastinal disorders | 2.1% (2 of 94) | 0.0% | 1 |
| Abdominal pain upper | Gastrointestinal disorders | 6.7% (2 of 30) | 3.3% | 1 |
| Diarrhoea | Gastrointestinal disorders | 6.7% (2 of 30) | 13.3% | 1 |
| Steatorrhoea | Gastrointestinal disorders | 6.7% (2 of 30) | 6.7% | 1 |
| Gastroenteritis | Infections and infestations | 6.7% (2 of 30) | 3.3% | 1 |
| Decreased appetite | Metabolism and nutrition disorders | 6.7% (2 of 30) | 6.7% | 1 |
| Wheezing | Respiratory, thoracic and mediastinal disorders | 0.8% (1 of 124) | 1.7% | 2 |
| Febrile neutropenia | Blood and lymphatic system disorders | 1.1% (1 of 94) | 1.1% | 1 |
| Leukocytosis | Blood and lymphatic system disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Pericardial effusion | Cardiac disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Hearing impaired | Ear and labyrinth disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Abdominal distension | Gastrointestinal disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Colonic obstruction | Gastrointestinal disorders | 1.1% (1 of 94) | 1.1% | 1 |
| Gastrointestinal disorders - Other, specify | Gastrointestinal disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Rectal hemorrhage | Gastrointestinal disorders | 1.1% (1 of 94) | 1.1% | 1 |
| Small intestinal obstruction | Gastrointestinal disorders | 1.1% (1 of 94) | 1.1% | 1 |
| Edema trunk | General disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Infusion related reaction | General disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Pain | General disorders | 1.1% (1 of 94) | 2.2% | 1 |
| Anorectal infection | Infections and infestations | 1.1% (1 of 94) | 0.0% | 1 |
| Bladder infection | Infections and infestations | 1.1% (1 of 94) | 0.0% | 1 |
| Enterocolitis infectious | Infections and infestations | 1.1% (1 of 94) | 0.0% | 1 |
| Nail infection | Infections and infestations | 1.1% (1 of 94) | 0.0% | 1 |
| Papulopustular rash | Infections and infestations | 1.1% (1 of 94) | 0.0% | 1 |
| Paronychia | Infections and infestations | 1.1% (1 of 94) | 0.0% | 1 |
| Sepsis | Infections and infestations | 1.1% (1 of 94) | 1.1% | 1 |
| Skin infection | Infections and infestations | 1.1% (1 of 94) | 0.0% | 1 |
| Soft tissue infection | Infections and infestations | 1.1% (1 of 94) | 0.0% | 1 |
| Tooth infection | Infections and infestations | 1.1% (1 of 94) | 0.0% | 1 |
| Aspartate aminotransferase increased | Investigations | 1.1% (1 of 94) | 1.1% | 1 |
| Hemoglobin increased | Investigations | 1.1% (1 of 94) | 1.1% | 1 |
| Weight gain | Investigations | 1.1% (1 of 94) | 0.0% | 1 |
| Dehydration | Metabolism and nutrition disorders | 1.1% (1 of 94) | 3.3% | 1 |
| Hypoalbuminemia | Metabolism and nutrition disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Hypokalemia | Metabolism and nutrition disorders | 1.1% (1 of 94) | 1.1% | 1 |
| Bone pain | Musculoskeletal and connective tissue disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Generalized muscle weakness | Musculoskeletal and connective tissue disorders | 1.1% (1 of 94) | 2.2% | 1 |
| Myalgia | Musculoskeletal and connective tissue disorders | 1.1% (1 of 94) | 2.2% | 1 |
| Dizziness | Nervous system disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Peripheral motor neuropathy | Nervous system disorders | 1.1% (1 of 94) | 1.1% | 1 |
| Anxiety | Psychiatric disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Depression | Psychiatric disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Hypoxia | Respiratory, thoracic and mediastinal disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | 1.1% (1 of 94) | 2.2% | 1 |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | 1.1% (1 of 94) | 1.1% | 1 |
| Dry skin | Skin and subcutaneous tissue disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Pruritus | Skin and subcutaneous tissue disorders | 1.1% (1 of 94) | 1.1% | 1 |
| Rash maculo-papular | Skin and subcutaneous tissue disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Urticaria | Skin and subcutaneous tissue disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Hot flashes | Vascular disorders | 1.1% (1 of 94) | 0.0% | 1 |
| Hypertension | Vascular disorders | 1.1% (1 of 94) | 6.6% | 1 |
| Influenza | Infections and infestations | 3.3% (1 of 30) | 6.7% | 1 |
| Productive cough | Respiratory, thoracic and mediastinal disorders | 3.3% (1 of 30) | 6.7% | 1 |
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | 3.3% (1 of 30) | 6.7% | 1 |
| Blood and lymphatic system disorders - Other, specify | Blood and lymphatic system disorders | 0.0% (0 of 94) | 1.1% | 1 |
| Atrial fibrillation | Cardiac disorders | 0.0% (0 of 94) | 1.1% | 1 |
| Heart failure | Cardiac disorders | 0.0% (0 of 94) | 1.1% | 1 |
| Pericardial tamponade | Cardiac disorders | 0.0% (0 of 94) | 1.1% | 1 |
| Diarrhea | Gastrointestinal disorders | 0.0% (0 of 94) | 3.3% | 1 |
| Duodenal perforation | Gastrointestinal disorders | 0.0% (0 of 94) | 1.1% | 1 |
| Lower gastrointestinal hemorrhage | Gastrointestinal disorders | 0.0% (0 of 94) | 1.1% | 1 |
| Rectal ulcer | Gastrointestinal disorders | 0.0% (0 of 94) | 1.1% | 1 |
| Upper gastrointestinal hemorrhage | Gastrointestinal disorders | 0.0% (0 of 94) | 1.1% | 1 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
QUESTIONS
Does glutathione cause neutrophil count decreased?
In 3 placebo-controlled trials with posted results, 23.4% of people on glutathione reported neutrophil count decreased, against 18.7% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does glutathione cause anemia?
In 3 placebo-controlled trials with posted results, 12.8% of people on glutathione reported anemia, against 16.5% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does glutathione cause peripheral sensory neuropathy?
In 3 placebo-controlled trials with posted results, 12.8% of people on glutathione reported peripheral sensory neuropathy, against 7.7% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does glutathione cause cough?
In 3 placebo-controlled trials with posted results, 11.3% of people on glutathione reported cough, against 10.7% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does glutathione cause fatigue?
In 3 placebo-controlled trials with posted results, 10.6% of people on glutathione reported fatigue, against 9.9% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
REGISTERED STUDIES
276 registered clinical trials of Glutathione
The 10 most recently updated are listed.
| NCT07304440 | Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study Status: RECRUITING · Updated 2026-09-22 |
|---|---|
| NCT04740580 | Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease Status: ACTIVE_NOT_RECRUITING · Updated 2026-09-09 |
| NCT03493178 | Glutathione in Mild Cognitive Impairment Status: ACTIVE_NOT_RECRUITING · Updated 2026-09-04 |
| NCT07792369 | 26DT052; Scaling Busulfan Dose to Body Surface Area in Children Status: NOT_YET_RECRUITING · Updated 2026-08-28 |
| NCT07162623 | Clinical Study to Assess Safety, Efficacy and In-Use Tolerability of Oziva Bioactive Gluta Fizzy Effervescent Tablets on Subjects With Facial Dark Spots Such as Pimple Marks, Sunspots, Age Spots and Uneven Skin Tone Status: COMPLETED · Updated 2026-08-06 |
| NCT05654922 | Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant Status: RECRUITING · Updated 2026-08-05 |
| NCT07748507 | Comparison of Gingival Depigmentation Using Microneedling and Microneedling With Glutathione Gel - A Split Mouth Clinical Trial Status: COMPLETED · Updated 2026-08-05 |
| NCT07477275 | Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation Status: COMPLETED · Updated 2026-07-31 |
| NCT04677972 | SPI-1005 for the Treatment of Meniere's Disease Status: COMPLETED · Updated 2026-07-23 |
| NCT07724067 | GLUT-F Improves MASLD Liver Function Status: COMPLETED · Updated 2026-07-23 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.